Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Arthritis care & research

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.20435PMID 21240966PMCID PMC3091984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Survey of Rheumatologists’ Practice for Prescribing Pneumocystis Prophylaxis

  2010cited by this paper
• Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection

  2010cited by this paper
• The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

  2010cited by this paper
• Increase in age at onset of giant cell arteritis: a population-based study

  2009cited by this paper
• Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?

  2009cited by this paper
• Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection

  2008cited by this paper
• Multiple opportunistic infections after high-dose steroid therapy for giant cell arteritis in a patient previously treated with a purine analog

  2006cited by this paper
• Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention

  2004cited by this paper
• Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.

  2003cited by this paper
• Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.

  2000cited by this paper
• Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.

  1999cited by this paper
• A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

  1997cited by this paper
• Opportunistic Infections in Patients with Temporal Arteritis Treated with Corticosteroids

  1997cited by this paper
• Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

  1996cited by this paper
• Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia.

  1996influential reference
• Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.

  1995cited by this paper
• Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases.

  1995cited by this paper
• Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis.

  1995cited by this paper
• Discrimination against people with HIVinfection and AIDS

  1994cited by this paper
• Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis.

  1991cited by this paper
• Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis.

  1991cited by this paper

• To prophylax or not to prophylax? The role of trimethoprim/sulfamethoxazole as a prophylactic agent in systemic vasculitis: the case of antineutrophil cytoplasmic antibody- associated vasculitis and giant cell arteritis.

  2025cites this paper
• Management of Relapses in Giant Cell Arteritis

  2024cites this paper
• Incidence of invasive fungal diseases in inflammatory bowel disease patients: A nationwide study in South Korea

  2024cites this paper
• Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients

  2023cites this paper
• Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

  2023cites this paper
• Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?

  2022cites this paper
• Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality

  2022cites this paper
• Duration of prednisone treatment before development of Pneumocystis jirovecii pneumonia in patients with vasculitis: A case series.

  2022cites this paper
• Giant cell arteritis treatment patterns and rates of serious infections.

  2021cites this paper
• Opinions on Pneumocystis jirovecii prophylaxis in autoimmune neuromuscular disorders

  2021influential citation
• My Treatment Approach to Giant Cell Arteritis.

  2021cites this paper
• Boundaries of a systemic disease: a protean presentation of giant cell arteritis

  2020cites this paper
• Pneumocystis jirovecii in immunocompromised patients with rheumatic diseases

  2020cites this paper
• S2k-Leitlinie: Management der Großgefäßvaskulitiden

  2020cites this paper
• Morbidity and Mortality of Large-Vessel Vasculitides

  2020cites this paper
• The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases

  2020cites this paper
• Pneumocystis jirovecii en pacientes inmunocomprometidos con enfermedades reumáticas

  2020cites this paper
• Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases.

  2020cites this paper
• Pneumocystis Jirovecii in Immunocompromised Patients with Rheumatic Diseases.

  2020cites this paper
• Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections

  2020cites this paper
• Comparison of Positive Results With End-Point and Real-Time Polymerase Chain Reaction Assays for the Diagnosis of Pneumocystis Pneumonia

  2020cites this paper
• Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases.

  2019cites this paper
• Updates in the Diagnosis and Management of Giant Cell Arteritis

  2019cites this paper
• Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis

  2019cites this paper
• Therapy and Management of Pneumocystis jirovecii Infection

  2018cites this paper
• Prevention of glucocorticoid morbidity in giant cell arteritis

  2018cites this paper
• Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.

  2018cites this paper
• Chapter 16 – Giant Cell Arteritis

  2017cites this paper
• Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

  2017cites this paper
• Giant Cell Arteritis: Current and Future Treatment Options

  2017cites this paper
• Infection Risk and Safety of Corticosteroid Use.

  2016cites this paper
• Pneumocystose chez les patients immunodéprimés non infectés par le VIH

  2016cites this paper
• [Pneumocystosis in non-HIV-infected immunocompromised patients].

  2016cites this paper
• Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.

  2016cites this paper
• Arteritis de células gigantes: diagnóstico y tratamiento

  2015cites this paper
• Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study.

  2015influential citation
• Cost-effectiveness of Prophylaxis Against Pneumocystisjiroveci Pneumonia in Patients with Crohn’s Disease

  2015cites this paper
• Rising Prevalence of Pneumocystis jirovecii Pneumonia Amongst the Non-HIV Immunosuppressed

  2015cites this paper
• Giant cell arteritis: Diagnosis and treatment

  2015cites this paper
• Giant cell arteritis: diagnosis and treatment.

  2015cites this paper
• neumocystose chez les patients immunodéprimés non infectés par e VIH neumocystosis in non-HIV-infected immunocompromised patients

  2015cites this paper
• [Large vessel vasculitis].

  2014cites this paper
• Persistence of inflammatory activity in giant cell arteritis:Role of the angiotensin II system

  2014cites this paper
• Pneumocystis jirovecii Pneumonia in Systemic Lupus Erythematosus From Southern Taiwan

  2013cites this paper
• A dose-escalation regimen of trimethoprim–sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases

  2013cites this paper
• Clinical features of a new disease concept, IgG4-related thyroiditis: comments on the article by Watanabe et al

  2013cites this paper
• Giant cell arteritis and disseminated tuberculosis: presentation of two cases

  2013cites this paper
• Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools

  2011cites this paper
• Reumatismo - The Italian Journal of Rheumatology

  year unknowncites this paper